COLO205 Transfection Reagent (Colon Carcinoma)

$388.00$2,082.00

Kit Size VolumePricePay with CC, PO, or PaypalAdd to Cart
0.5 ml (Catalog #6452)$388.00
1.5 ml (Catalog #6453)$794.00
1.5 ml CRISPR (Catalog #2132)$794.00
8.0 ml (Catalog #7032)$2,082.00
SKU: COLO205 Category:

Description

Product Availability: In Stock (FedEx delivery within 2 business days).

Ordering: To place an order please use Add to Cart button (account not required).


Transfection Reagent for COLO-205 Cells (Colon Adenocarcinoma Cell, CCL-222)

  • A nanoparticle-based liposome formulation
  • Transfection protocols provided for transfection of proteins, DNA, mRNA, siRNA, shRNA and microRNA
  • Produce higher level of recombinant protein expression with minimal disruption of normal cell function
  • Generate physiologically relevant data you can trust
  • Effective for plasmid DNA/siRNA co-transfection
  • Easy-to-use transfection protocol with reproducible results
  • Low cytotoxicity
  • Download in vitro COLO205 transfection protocol: [PDF]
  • Download COLO205 CRISPR/Cas9 transfection protocol: [PDF]
  • Download PowerPoint presentation for COLO-205 cells transfection kit: [PPT]
  • UPC/GTIN/EAN: 860002089741
  • Brand: ALTOGEN®, developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 91% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Product Description:

Optimized transfection reagent for COLO205 cells high transfection efficiency and low cytotoxicity. Transfection kit for human colon adenocarcinoma cell line.

Transfection Protocol and SDS:

Download Altogen Biosystems COLO-205 Transfection Protocol: [PDF]

Download SDS: [PDF]

COLO-205 Cell Line:

Colon cancer is the third most prevalent cancer globally and the second primary cause of cancer-related deaths that is reportedly responsible for more than 50,000 fatalities every year in the United States alone. The lifetime risk of developing colon cancer is slightly lower in women than in men, as stated by the American Cancer Society (ACS). The COLO-205 cell line was established in 1975 from a 70-year-old Caucasian male patient with colon cancer. These cells exhibit epithelial cell morphology and come from a Dukes’ type D tumor. The patient had been treated with 5-fluorouracil for approximately five weeks before removal of the specimen. Also, the cells have been tested negative for CSAp, positive for keratin, and express a 36,000-dalton cell surface glycoprotein, which has a related antigen. The COLO-205 cell line is similar to COLO 201 and was derived from the same patient. In addition to being an adequate host for studying colon cancer, this cell line is utilized for researching the SV-40 monkey virus. Moreover, in biochemistry, the COLO-205 cell line is used for transfection and has applications for the production of recombinant proteins. Altogen Biosystems provides transfection reagent kits for the COLO-205 colon cancer cell line. The nanoparticle-based reagents have demonstrated high efficiency and low cytotoxicity.

Colo205 is a human colon adenocarcinoma cell line that was established from a metastatic site of colon cancer. This cell line is widely used in cancer research to investigate the biology and treatment of colon cancer. The Colo205 cell line has been characterized as having a high degree of chromosomal instability, which is a hallmark of many cancer cells. Researchers use this cell line to study the molecular mechanisms underlying the development and progression of colon cancer, as well as to test the effects of potential therapeutics on cancer cells. Colo205 cell line is a valuable tool for cancer researchers and has contributed to many advances in our understanding of the biology and treatment of colon cancer. However, it is important to note that cell lines may not fully recapitulate the complexity of primary tumors, and results obtained from cell line studies should be validated in animal models and patient samples.

Mutations:

BRAF 673 37 7 140453136 140453136 Missense_Mutation SNP A T
CDH8 1006 37 16 62055071 62055071 Silent SNP C T
ZNF480 147657 37 19 52825759 52825759 Missense_Mutation SNP G T
MPDZ 8777 37 9 13119542 13119542 Missense_Mutation SNP C T
GJA9 81025 37 1 39340690 39340690 Nonsense_Mutation SNP C A
NSG2 0 37 5 173534384 173534384 Missense_Mutation SNP G A
ASTN2 23245 37 9 119976858 119976858 Missense_Mutation SNP C T
PRKCZ 5590 37 1 2087523 2087523 Silent SNP G A
TAS1R1 80835 37 1 6637034 6637034 Missense_Mutation SNP G A
ANGPTL7 10218 37 1 11253831 11253831 Splice_Site SNP G A
MTOR 2475 37 1 11270947 11270947 Missense_Mutation SNP G A
PTCHD2 57540 37 1 11562879 11562879 Missense_Mutation SNP G A
LCK 3932 37 1 32740628 32740628 Silent SNP C T
KANK4 163782 37 1 62734099 62734099 Missense_Mutation SNP C A
GSTM2 2946 37 1 110251189 110251189 Silent SNP G A

Data:

COLO205 Cell Transfection Reagent

Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into COLO-205 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).

Colo205-cells-transfection-protocol

Figure 2. Protein expression of Lamin A/C in COLO-205 cells. DNA plasmid expressing Lamin A/C or siRNA targeting Lamin A/C were transfected into COLO-205 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Altogen Biosystems provides preoptimized transfection products for life science research applications. Transfection protocols are optimized for individual cancer cell lines. Altogen Biosystems developed two types of in vivo delivery kits for animal research: Tissue-targeted reagents (delivery to liver, pancreas, and kidney tissues), and broad range in vivo delivery reagents (PEG-Liposome, Nanoparticle-based, Lipid-based, and Polymer-based kits). Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, RNA, and any other negatively charged molecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource. Altogen Labs provides good laboratory practice (GLP) compliant preclinical research services for IND applications and drug development. Our biology CRO services includes both efficacy studies (over 90 in-house validated xenograft models) and safety pharmacology/toxicology studies.

COLO205 Transfection Reagent

Volume Options:

  • 0.5 ml (Catalog #6452)
  • 1.5 ml (Catalog #6453)
  • 1.5 ml CRISPR (Catalog #2132)
  • 8.0 ml (Catalog #7032)

Additional information

Weight 1 lbs
Dimensions 4 × 3 × 0.2 in
Kit Size (Volume)

0.5 ml (Catalog #6452), 1.5 ml (Catalog #6453), 1.5 ml CRISPR (Catalog #2132), 8.0 ml (Catalog #7032)